| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013654649 |
| P356 | DOI | 10.1007/S11926-012-0275-1 |
| P8608 | Fatcat ID | release_o42k4elfcffd3jta26g6czhcz4 |
| P932 | PMC publication ID | 3616381 |
| P698 | PubMed publication ID | 22773387 |
| P50 | author | Kevin D Deane | Q89587685 |
| P2093 | author name string | M Kristen Demoruelle | |
| P2860 | cites work | 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis | Q26828418 |
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. | Q33206727 | ||
| A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial | Q33675468 | ||
| Combination DMARD therapy including corticosteroids in early rheumatoid arthritis. | Q33789189 | ||
| Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation | Q33890221 | ||
| In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial | Q34022672 | ||
| The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner | Q34307377 | ||
| Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. | Q34317049 | ||
| Treating rheumatoid arthritis to target: recommendations of an international task force | Q34462557 | ||
| Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial | Q34651182 | ||
| Early rheumatoid arthritis -- is there a window of opportunity? | Q36994326 | ||
| Prevention of autoimmune rheumatic disease: state of the art and future perspectives | Q37811620 | ||
| The value of early intervention in RA--a window of opportunity | Q37847069 | ||
| Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? | Q37865848 | ||
| The need to better classify and diagnose early and very early rheumatoid arthritis | Q37969003 | ||
| Lag time between onset of symptoms and access to rheumatology care and DMARD therapy in a cohort of patients with rheumatoid arthritis. | Q39549861 | ||
| Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors | Q40532147 | ||
| Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis. | Q41917701 | ||
| Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies | Q41918491 | ||
| Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group | Q41924053 | ||
| Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial | Q41937791 | ||
| The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis | Q43132769 | ||
| Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: results of the STIVEA trial. | Q43262248 | ||
| Combination etanercept and methotrexate provides better disease control in very early (<=4 months) versus early rheumatoid arthritis (>4 months and <2 years): post hoc analyses from the COMET study | Q43630815 | ||
| Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. | Q43692514 | ||
| Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis | Q44616885 | ||
| Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. | Q46343375 | ||
| Dating the "window of therapeutic opportunity" in early rheumatoid arthritis: accuracy of patient recall of arthritis symptom onset. | Q46574555 | ||
| Repair of joint erosions in rheumatoid arthritis: prevalence and patient characteristics in a large inception cohort. | Q47766604 | ||
| Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. | Q48016298 | ||
| Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: a randomised trial | Q48016308 | ||
| Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. | Q50793569 | ||
| Predictors of response to methotrexate in early DMARD naive rheumatoid arthritis: results from the initial open-label phase of the SWEFOT trial. | Q51528833 | ||
| Delays in assessment of patients with rheumatoid arthritis: variations across Europe. | Q52893591 | ||
| 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q56506042 | ||
| Long-term impact of delay in assessment of patients with early arthritis | Q57788506 | ||
| A prediction rule for disease outcome in patients with Recent-onset undifferentiated arthritis: How to guide individual treatment decisions | Q57788773 | ||
| Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: Results from two large early arthritis cohorts | Q58234860 | ||
| Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial | Q58234944 | ||
| Antifilaggrin antibodies within "normal" range predict rheumatoid arthritis in a linear fashion | Q73324305 | ||
| Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration | Q73374696 | ||
| Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial | Q80607339 | ||
| The need for new classification criteria for rheumatoid arthritis | Q81412918 | ||
| The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had | Q82132610 | ||
| Classification of rheumatoid arthritis: comparison of the 1987 American College of Rheumatology criteria and the 2010 American College of Rheumatology/European League Against Rheumatism criteria | Q85241547 | ||
| P433 | issue | 5 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 472-480 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Current Rheumatology Reports | Q23930052 |
| P1476 | title | Treatment strategies in early rheumatoid arthritis and prevention of rheumatoid arthritis | |
| P478 | volume | 14 |
| Q37742051 | An open randomized active-controlled clinical trial with low-dose SKA cytokines versus DMARDs evaluating low disease activity maintenance in patients with rheumatoid arthritis |
| Q64970218 | Application of GC/MS-Based Metabonomic Profiling in Studying the Therapeutic Effects of Aconitum carmichaeli with Ampelopsis japonica Extract on Collagen-Induced Arthritis in Rats. |
| Q99407057 | Association of Use of Rehabilitation Services With Development of Dementia Among Patients With Rheumatoid Arthritis: Analysis of Domestic Data in Taiwan |
| Q37492376 | Autoimmunity to citrullinated proteins and the initiation of rheumatoid arthritis |
| Q35766220 | Clinimetric properties of the Chinese version of the early inflammatory arthritis detection tool |
| Q57752989 | Detection of bone erosions in early rheumatoid arthritis: 3D ultrasonography versus computed tomography |
| Q40479806 | Factors affecting well-being in adults recently diagnosed with rheumatoid arthritis. |
| Q47733654 | Factors influencing remission in rheumatoid arthritis patients: results from Karnataka rheumatoid arthritis comorbidity (KRAC) study |
| Q37236822 | Induction maintenance with tumour necrosis factor-inhibitor combination therapy with discontinuation versus methotrexate monotherapy in early rheumatoid arthritis: a systematic review and meta-analysis of efficacy in randomised controlled trials |
| Q38554197 | Lipid and Metabolic Changes in Rheumatoid Arthritis. |
| Q91851036 | N-Linked Glycans in the Variable Domain of IgG Anti-Citrullinated Protein Antibodies Predict the Development of Rheumatoid Arthritis |
| Q27003201 | Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE |
| Q92464804 | Perceptions of first-degree relatives of patients with rheumatoid arthritis about lifestyle modifications and pharmacological interventions to reduce the risk of rheumatoid arthritis development: a qualitative interview study |
| Q37179639 | Performance of anti-cyclic citrullinated Peptide assays differs in subjects at increased risk of rheumatoid arthritis and subjects with established disease |
| Q92464722 | Perspectives of patients, first-degree relatives and rheumatologists on preventive treatments for rheumatoid arthritis: a qualitative analysis |
| Q41464826 | Prevalence of Asymptomatic Arterial Hypertension and Its Correlation with Inflammatory Activity in Early Rheumatoid Arthritis. |
| Q64090428 | Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals |
| Q45977173 | Switching therapies in multiple sclerosis. |
| Q97424914 | Synoviocyte-targeted therapy synergizes with TNF inhibition in arthritis reversal |
| Q38837199 | System A amino acid transporters regulate glutamine uptake and attenuate antibody-mediated arthritis |
| Q89947863 | T-cell subset abnormalities predict progression along the Inflammatory Arthritis disease continuum: implications for management |
| Q43194836 | Targeting mechanisms at sites of complement activation for imaging and therapy |
| Q39976803 | The Challenge of Treating Early-Stage Rheumatoid Arthritis: The Contribution of Mixed Treatment Comparison to Choosing Appropriate Biologic Agents |
| Q39815843 | Treatment of rheumatoid arthritis (RA) in India-how and by whom: results from a speciality clinic-use of low-dose methotrexate (MTX) was inexplicably suboptimal. |
Search more.